What Makes Companies Do the Right Thing?
MIT Sloan Management Review|Fall 2024
Vaccine makers varied widely in their engagement with global public health efforts to broaden access to COVID-19 immunizations. Ethically motivated leadership was a dominant factor.
N. Craig Smith and Markus Scholz
What Makes Companies Do the Right Thing?

BUSINESS EXECUTIVES FACE NO starker test of their leadership than when confronting the choice between capturing profits and saving lives.

Pharmaceutical companies generated billions of dollars in additional revenue from the COVID-19 vaccine, buoyed by bidding wars between wealthy countries as the virus spread across the planet.¹ Faced with unparalleled demand, deals were being locked in even before the vaccines were developed. And once distribution started, vaccine hoarding began. Some countries had enough vaccines to vaccinate their populations several times over. As a result, millions of doses passed their use-by date and were thrown away, while people in poorer economies remained unvaccinated.

More than 1 million deaths in lower- and middle-income countries could have been avoided if COVID-19 vaccines had been shared more equitably in the first year they became available, according to retrospective modeling with vaccine distribution data from 2021.² Whether this figure can be solely attributed to inequitable distribution by vaccine manufacturers or other factors came into play such as the lack of cold storage and health infrastructure during distribution is up for debate. However, a significant number of lives were undoubtedly lost because vaccines did not reach people who needed them.

It is easy to blame the aggressive efforts of wealthier nations to ensure their own supply of vaccines for this striking inequity. But our inquiry, conducted as the pandemic unfolded and focused on the vaccine producers, suggests pharma companies could have done a lot more to combat the rush by wealthy countries to vaccinate their own people.³

Esta historia es de la edición Fall 2024 de MIT Sloan Management Review.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

Esta historia es de la edición Fall 2024 de MIT Sloan Management Review.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

MÁS HISTORIAS DE MIT SLOAN MANAGEMENT REVIEWVer todo
Avoiding Harm in Technology Innovation
MIT Sloan Management Review

Avoiding Harm in Technology Innovation

To capitalize on emerging technologies while mitigating unanticipated consequences, innovation managers need to establish a systematic review process.

time-read
10+ minutos  |
Fall 2024
Make a Stronger Business Case for Sustainability
MIT Sloan Management Review

Make a Stronger Business Case for Sustainability

When greener products and processes add costs, managers can shift other levers to maintain profitability.

time-read
9 minutos  |
Fall 2024
How to Turn Professional Services Into Products
MIT Sloan Management Review

How to Turn Professional Services Into Products

Product-based business models can help services firms achieve greater scale and profitability. But the transformation can be challenging.

time-read
10 minutos  |
Fall 2024
Do You Really Need a Chief AI Officer?
MIT Sloan Management Review

Do You Really Need a Chief AI Officer?

The right answer depends on the strategic importance and maturity of AI in your company.

time-read
10+ minutos  |
Fall 2024
Where To Next? Opportunity on the Edge
MIT Sloan Management Review

Where To Next? Opportunity on the Edge

Doing business in regions considered less stable or developed can pay off for companies. But they must invest in working with local communities.

time-read
10 minutos  |
Fall 2024
Make Smarter Investments in Resilient Supply Chains
MIT Sloan Management Review

Make Smarter Investments in Resilient Supply Chains

Many companies invest in resilience only after a disruption. Applying the concept of real options can help decision makers fortify supply chain capabilities no matter the crisis.

time-read
10+ minutos  |
Fall 2024
The Three Traps That Stymie Reinvention
MIT Sloan Management Review

The Three Traps That Stymie Reinvention

Organizational identity, architecture, and collaboration can be either assets or liabilities to pursuing growth in new sectors.

time-read
10+ minutos  |
Fall 2024
What Makes Companies Do the Right Thing?
MIT Sloan Management Review

What Makes Companies Do the Right Thing?

Vaccine makers varied widely in their engagement with global public health efforts to broaden access to COVID-19 immunizations. Ethically motivated leadership was a dominant factor.

time-read
10+ minutos  |
Fall 2024
Build the Right C-Suite Team for Your Strategy
MIT Sloan Management Review

Build the Right C-Suite Team for Your Strategy

CEOs can foster a more effective leadership team by understanding when to tap senior executives' competitive instincts and when to encourage collaboration.

time-read
10+ minutos  |
Fall 2024
A Better Way to Unlock Innovation and Drive Change
MIT Sloan Management Review

A Better Way to Unlock Innovation and Drive Change

A strengths-based approach to building teams can win employee commitment to change and foster an inclusive, agile culture.

time-read
10+ minutos  |
Fall 2024